AAAAAA

   
Results: 1-16 |
Results: 16
FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS
Authors: BOKEMEYER C HARSTRICK A BEYER J METZNER B RUTHER U HARTMANN JT HOLSTEIN K DERIGS HG DEWIT R CASPER J SCHOFFSKI P KUHRER I ILLIGER HJ KEMPF B REICHLE A FOLLER A HOSSFELD DK FISCHER JT BERDEL W GERHARTZ H KIRCHNER H PFLUGER K OSTERMANN H KANZ L SCHMOLL HJ
Citation: C. Bokemeyer et al., FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Onkologie, 21, 1998, pp. 23-25
THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS
Authors: BOKEMEYER C HARSTRICK A BEYER J METZNER B RUTHER U HARTMANN JT HOLSTEIN K DERIGS HG DEWIT R CASPER J SCHOFFSKI P KUHRER I ILLIGER HJ KEMPF B REICHLE A FOLLER A HOSSFELD DK FISCHER JT BERDEL WE GERHARTZ HH KIRCHNER H PFLUGER KH OSTERMANN H KANZ L SCHMOLL HJ
Citation: C. Bokemeyer et al., THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Seminars in oncology, 25(2), 1998, pp. 24-32
LONG-TERM COMPLETE REMISSIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES DURING COMBINATION TREATMENT USING ALL-TRANS-RETINOIC ACID
Authors: HOFMANN WK GANSER A OTTMANN OG SEIPELT G ZANDER C FISCHER JT HOFFKEN K HOFFMANN K HOELZER D
Citation: Wk. Hofmann et al., LONG-TERM COMPLETE REMISSIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES DURING COMBINATION TREATMENT USING ALL-TRANS-RETINOIC ACID, British Journal of Haematology, 102(1), 1998, pp. 343-343
MITOXANTRONE (N) VS. 5-FLUOROURACIL EPIRUBICIN/CYCLOPHOSPHAMIDE (FEC)AS FIRST LINE THERAPY IN HIGH-RISK METASTATIC BREAST-CANCER/
Authors: VONMINCKWITZ G HEIDEMANN E SOUCHON R SAMONIGG H HIRSCHMANN WD BODENSTEIN H SCHINDLER A SCHULZE M CLEMENS H KONIG M SCHARL A FISCHER JT KAUFMANN M
Citation: G. Vonminckwitz et al., MITOXANTRONE (N) VS. 5-FLUOROURACIL EPIRUBICIN/CYCLOPHOSPHAMIDE (FEC)AS FIRST LINE THERAPY IN HIGH-RISK METASTATIC BREAST-CANCER/, European journal of cancer, 33, 1997, pp. 646-646
PHASE-II EVALUATION OF 5-FLUOROURACIL PLUS FOLINIC ACID AND ALPHA-2B-INTERFERON IN METASTATIC COLORECTAL-CANCER
Authors: KOHNE CH WILKE H HIDDEMANN W BOKEMEYER C LOHRMANN HP BODENSTEIN H PREISS J RAUSCHECKER H HILL H KAUFER C FISCHER JT OHL U URBANITZ D BALLEISEN L SCHMOLL HJ
Citation: Ch. Kohne et al., PHASE-II EVALUATION OF 5-FLUOROURACIL PLUS FOLINIC ACID AND ALPHA-2B-INTERFERON IN METASTATIC COLORECTAL-CANCER, Oncology, 54(2), 1997, pp. 96-101
SUCCESSFUL COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA FOLLOWING EARLY CONSOLIDATION THERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR-SUPPORTED HIGH-DOSE CYTARABINE AND MITOXANTRONE
Authors: SCHLENK RF DOHNER H PFORSICH M BENNER A FISCHER K HARTMAN F FISCHER JT WEBER W GUNZER U PRALLE H HAAS R
Citation: Rf. Schlenk et al., SUCCESSFUL COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA FOLLOWING EARLY CONSOLIDATION THERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR-SUPPORTED HIGH-DOSE CYTARABINE AND MITOXANTRONE, British Journal of Haematology, 99(2), 1997, pp. 386-393
ALL-TRANS-RETINOIC ACID (ATRA), INTERFERON-ALPHA (IFN-ALPHA) AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) AS COMBINATION THERAPY IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS)
Authors: HOFMANN WK GANSER A OTTMANN OG SEIPELT G ZANDER C GEISSLER RG FISCHER JT HOFFKEN K HOFFMANN K HOELZER D
Citation: Wk. Hofmann et al., ALL-TRANS-RETINOIC ACID (ATRA), INTERFERON-ALPHA (IFN-ALPHA) AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) AS COMBINATION THERAPY IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS), Blood, 90(10), 1997, pp. 366-366
SUCCESSFUL COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ONE OR 2 CYCLES OF CONSOLIDATION THERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR-SUPPORTED HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM)
Authors: SCHLENK R HARTMANN F MOOS M PFORSICH M FISCHER K BENNER A FISCHER JT WEBER W GUNZER U PRALLE H HAAS R DOHNER H
Citation: R. Schlenk et al., SUCCESSFUL COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ONE OR 2 CYCLES OF CONSOLIDATION THERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR-SUPPORTED HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM), Blood, 90(10), 1997, pp. 430-430
STRATIFICATION OF POSTREMISSION THERAPY IN ADULT ACUTE MYELOID-LEUKEMIA ACCORDING TO THE KARYOTYPE - FIRST RESULTS OF THE AML HD93 MULTICENTER TREATMENT TRIAL
Authors: DOHNER H FISCHER K DELVALLE F HARTMANN F PRALLE H FISCHER JT GUNZER U PEZZUTTO A WEBER N GRIMMINGER W PREISS J HAAS R SCHLENK R
Citation: H. Dohner et al., STRATIFICATION OF POSTREMISSION THERAPY IN ADULT ACUTE MYELOID-LEUKEMIA ACCORDING TO THE KARYOTYPE - FIRST RESULTS OF THE AML HD93 MULTICENTER TREATMENT TRIAL, Blood, 90(10), 1997, pp. 2598-2598
G-CSF-PRIMING COMBINED WITH CHEMOTHERAPY (IDARUBICIN, ARA-C, VP-16) YIELDS HIGH REMISSION RATES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES AND HIGH-RISK AML
Authors: GANSER A HOFMANN WK HEIL G OTTMANN OG FISCHER JT LANGER W HERRMANN WK KNUTH A HOFFKEN K KOLBE K SCHMOLL HJ HERTENSTEIN B HOELZER D
Citation: A. Ganser et al., G-CSF-PRIMING COMBINED WITH CHEMOTHERAPY (IDARUBICIN, ARA-C, VP-16) YIELDS HIGH REMISSION RATES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES AND HIGH-RISK AML, Blood, 88(10), 1996, pp. 834-834
A COMPARISON OF POLYCHEMOTHERAPY AND MELPHALAN PREDNISONE FOR PRIMARYREMISSION INDUCTION, AND INTERFERON-ALPHA FOR MAINTENANCE TREATMENT, IN MULTIPLE-MYELOMA - A PROSPECTIVE TRIAL OF THE GERMAN MYELOMA TREATMENT GROUP
Authors: PEEST D DEICHER H COLDEWEY R LEO R BARTL R BARTELS H BRAUN HJ FETT W FISCHER JT GOBEL B HARMS P HENKE R HOFFMANN L KREUSER ED MAIER WD MEIER CR OERTEL J PETIT M PLANKER M PLATZECK C RESPONDEK M SCHAFER E SCHUMACHER K STENNES M STENZINGER W TIRIER C WAGNER H WEH HJ VONWUSSOW P WYSK J
Citation: D. Peest et al., A COMPARISON OF POLYCHEMOTHERAPY AND MELPHALAN PREDNISONE FOR PRIMARYREMISSION INDUCTION, AND INTERFERON-ALPHA FOR MAINTENANCE TREATMENT, IN MULTIPLE-MYELOMA - A PROSPECTIVE TRIAL OF THE GERMAN MYELOMA TREATMENT GROUP, European journal of cancer, 31A(2), 1995, pp. 146-151
A DOSE COMPARISON STUDY OF DIDANOSINE IN PATIENTS WITH VERY ADVANCED HIV-INFECTION WHO ARE INTOLERANT TO OR CLINICALLY DETERIORATE ON ZIDOVUDINE
Authors: JABLONOWSKI H ARASTEH K STASZEWSKI S RUF B STELLBRINK HJ SCHRAPPE M STOEHR A HAASE W SCHOMAKER U ROTHE BV THOMIS J STILLE W LAGE M POHLE HD ALBRECHT H FATKENHEUER G DIEHL V PLETTENBERG A SCHUSTER D KNECHTEN H RUHNKE M ALEXANDER M SCHWANDER S DIETRICH M RUBBERT A KALDEN JR EMMINGER C EICHENLAUB D SCHEDEL I DEICHER H HEHLMANN R RASOKAT H DENGLER HJ HOFFKEN G BROCKHAUS W ZIDEK W WILKE G FISCHER JT ULMER A PETZOLDT D PEES HW ZANGERLE R DUNCKER D KRIPPNER H RIEGER T KERN P
Citation: H. Jablonowski et al., A DOSE COMPARISON STUDY OF DIDANOSINE IN PATIENTS WITH VERY ADVANCED HIV-INFECTION WHO ARE INTOLERANT TO OR CLINICALLY DETERIORATE ON ZIDOVUDINE, AIDS, 9(5), 1995, pp. 463-469
AGGRESSIVE CHEMOTHERAPY WITH IDARUBICIN, ARA-C, VP-16, AMSACRIN, FOLLOWED BY G-CSF AND MAINTENANCE IMMUNOTHERAPY WITH INTERLEUKIN-2 FOR ADVANCED MYELODYSPLASTIC SYNDROMES AND HIGH-RISK ANLL
Authors: GANSER A HEIL G HOFMANN WK OTTMANN OG SEIPELT G FISCHER JT LANGER W BROCKHAUS W ITTEL TH BRACK N KNUTH A HOFFKEN K KLAUSMANN M FUHR HG BERGMANN L HOELZER D
Citation: A. Ganser et al., AGGRESSIVE CHEMOTHERAPY WITH IDARUBICIN, ARA-C, VP-16, AMSACRIN, FOLLOWED BY G-CSF AND MAINTENANCE IMMUNOTHERAPY WITH INTERLEUKIN-2 FOR ADVANCED MYELODYSPLASTIC SYNDROMES AND HIGH-RISK ANLL, Blood, 86(10), 1995, pp. 1722-1722
TREATMENT INTENSIFICATION WITH R-METHUG-CSF IN HIGH-GRADE MALIGNANT NON-HODGKINS-LYMPHOMAS
Authors: STEINKE B MUNZ A MANEGOLD C FREUND M REINOLD HM FISCHER JT ARNOLD H LENGFELDER E LUTZ M HECHT T ZWINGERS T
Citation: B. Steinke et al., TREATMENT INTENSIFICATION WITH R-METHUG-CSF IN HIGH-GRADE MALIGNANT NON-HODGKINS-LYMPHOMAS, Onkologie, 17(3), 1994, pp. 248-253
IDARUBICIN CYTOSINE ARABINOSIDE AND MITOXANTRONE/ETOPOSIDE FOR THE TREATMENT OF DE-NOVO ACUTE MYELOGENOUS LEUKEMIA/
Authors: HAAS R HO AD DELVALLE F FISCHER JT EHRHARDT R DOHNER H WITT B HUBERTS H KAPLAN E HUNSTEIN W
Citation: R. Haas et al., IDARUBICIN CYTOSINE ARABINOSIDE AND MITOXANTRONE/ETOPOSIDE FOR THE TREATMENT OF DE-NOVO ACUTE MYELOGENOUS LEUKEMIA/, Seminars in oncology, 20(6), 1993, pp. 20-26
AGGRESSIVE INDUCTION CHEMOTHERAPY WITH IDARUBICIN, ARA-C, VP-16, FOLLOWED BY G-CSF AND MAINTENANCE IMMUNOTHERAPY WITH INTERLEUKIN-2 FOR HIGH-RISK ANLL
Authors: GANSER A HEIL G SEIPELT G FISCHER JT LANGER G BROCKHAUS W ITTEL TH FUHR HG BERGMANN L HOELZER D
Citation: A. Ganser et al., AGGRESSIVE INDUCTION CHEMOTHERAPY WITH IDARUBICIN, ARA-C, VP-16, FOLLOWED BY G-CSF AND MAINTENANCE IMMUNOTHERAPY WITH INTERLEUKIN-2 FOR HIGH-RISK ANLL, Blood, 82(10), 1993, pp. 10000128-10000128
Risultati: 1-16 |